Lexeo Therapeutics (LXEO) Institutional Ownership → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free LXEO Stock Alerts $12.50 +0.34 (+2.80%) (As of 04/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Lexeo Therapeutics (NASDAQ:LXEO)CurrentInstitutional OwnershipPercentage60.67%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$78.60MNumber ofInstitutional Sellers(last 12 months)0 Get LXEO Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexeo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Prosper Trading AcademyThis AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?Click Here To Get Your Free Copy Lexeo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/20/2024Eventide Asset Management LLC3,002,831$40.30M0.7%N/A11.268% 2/15/2024Omega Fund Management LLC2,157,623$28.96M23.5%N/A8.096% 2/15/2024Blackstone Inc.696,110$9.34M0.0%N/A2.612% (Data available from 1/1/2016 forward) LXEO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LXEO shares? During the previous two years, the following institutional investors and hedge funds held shares of Lexeo Therapeutics shares: Eventide Asset Management LLC ($40.30M), and Omega Fund Management LLC ($28.96M), Blackstone Inc. ($9.34M).Learn more on LXEO's institutional investors. What percentage of Lexeo Therapeutics stock is owned by institutional investors? 60.67% of Lexeo Therapeutics stock is owned by institutional investors. Learn more on LXEO's institutional investor holdings. Which institutional investors have been buying Lexeo Therapeutics stock? The following institutional investors have purchased Lexeo Therapeutics stock in the last 24 months: Eventide Asset Management LLC ($3.00M), Omega Fund Management LLC ($2.16M), and Blackstone Inc. ($696.11K). How much institutional buying is happening at Lexeo Therapeutics? Institutional investors have bought a total of 5,856,564 shares in the last 24 months. This purchase volume represents approximately $78.60M in transactions. Related Companies: Alvotech Institutional Ownership Tourmaline Bio Institutional Ownership Voyager Therapeutics Institutional Ownership iTeos Therapeutics Institutional Ownership Humacyte Institutional Ownership Replimune Group Institutional Ownership Caribou Biosciences Institutional Ownership Solid Biosciences Institutional Ownership Jasper Therapeutics Institutional Ownership Aura Biosciences Institutional Ownership This page (NASDAQ:LXEO) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
